NewLink Genetics Corp Company Profile (NASDAQ:NLNK)

About NewLink Genetics Corp (NASDAQ:NLNK)

NewLink Genetics Corp logoNewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company's portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells. Its additional HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma, respectively. Additionally, it has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system's tolerance to cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:NLNK
  • CUSIP: 65151110
  • Web: www.newlinkgenetics.com
Capitalization:
  • Market Cap: $419.09 million
  • Outstanding Shares: 29,225,000
Average Prices:
  • 50 Day Moving Avg: $16.81
  • 200 Day Moving Avg: $15.09
  • 52 Week Range: $9.66 - $25.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -6.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.82 million
  • Price / Sales: 12.77
  • Book Value: $3.91 per share
  • Price / Book: 3.67
Profitability:
  • EBIDTA: ($73,110,000.00)
  • Net Margins: -303.49%
  • Return on Equity: -56.48%
  • Return on Assets: -47.55%
Debt:
  • Current Ratio: 4.41%
  • Quick Ratio: 4.41%
Misc:
  • Average Volume: 718,973 shs.
  • Beta: 1.12
  • Short Ratio: 5.64
 

Frequently Asked Questions for NewLink Genetics Corp (NASDAQ:NLNK)

What is NewLink Genetics Corp's stock symbol?

NewLink Genetics Corp trades on the NASDAQ under the ticker symbol "NLNK."

How were NewLink Genetics Corp's earnings last quarter?

NewLink Genetics Corp (NASDAQ:NLNK) issued its quarterly earnings results on Thursday, May, 4th. The company reported ($0.72) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.82) by $0.10. The company earned $2.76 million during the quarter, compared to analyst estimates of $2.68 million. NewLink Genetics Corp had a negative net margin of 303.49% and a negative return on equity of 56.48%. View NewLink Genetics Corp's Earnings History.

Where is NewLink Genetics Corp's stock going? Where will NewLink Genetics Corp's stock price be in 2017?

5 brokerages have issued twelve-month price targets for NewLink Genetics Corp's stock. Their predictions range from $18.00 to $32.00. On average, they expect NewLink Genetics Corp's share price to reach $26.50 in the next year. View Analyst Ratings for NewLink Genetics Corp.

What are analysts saying about NewLink Genetics Corp stock?

Here are some recent quotes from research analysts about NewLink Genetics Corp stock:

  • 1. According to Zacks Investment Research, "NewLink Genetics Corporation is a biopharmaceutical company which focuses on discovering, developing and commercializing immunotherapeutic products for cancer treatment. Its portfolio also includes biologic and small-molecule immunotherapy products used for the treatment of oncology indications. NewLink Genetics Corporation is headquartered in Ames, Iowa. " (5/10/2017)
  • 2. Stifel Nicolaus analysts commented, "NLNK shares are looking increasingly actionable ahead of what we believe could prove to be a transformational next 1-6 months ' highlighted by two indoximod-related presentations at the upcoming AACR meeting and a critical mid-FY17 data disclosure from partner Roche. We believe incremental data from the P2 trial evaluating the combination of indoximod/pembrolizumab will provide an apples/apples comparison to Incyte/Merck's epacadostat/pembrolizumab P2 melanoma data ' potentially dispelling the prevailing 'I DON'T' inhibitor thesis and providing a future runway for value attribution (now made even easier with the recent filing of additional formulation-related IP). We believe P1b data from the Roche development program evaluating the combination of atezolizumab/GDC-0919 may represent the first mechanistic/translational evidence supporting the contribution of IDO inhibition to an immunotherapy-based regimen ' significantly improving visibility into a meaningful stream of future non-dilutive revenue. Target increased to $26 (previously $22)." (3/1/2017)
  • 3. Jefferies Group LLC analysts commented, "NLNK plans to present more data on indoximod throughout 2017. At AACR in April there will be updated data on the pembro combo in melanoma with some baseline characteristics as well as preclinical data on the prodrug formulation of indoximod. Titles of these abstracts will be released tomorrow at 4:30pm. Additional data will be seen from the panc cancer trial combo with gem/ Abraxane in 2H17. We continue to await data from the GDC-0919 program." (3/1/2017)

Are investors shorting NewLink Genetics Corp?

NewLink Genetics Corp saw a increase in short interest in the month of April. As of April 28th, there was short interest totalling 3,640,962 shares, an increase of 31.5% from the April 13th total of 2,768,189 shares. Based on an average daily volume of 950,457 shares, the days-to-cover ratio is presently 3.8 days. Currently, 16.9% of the company's stock are short sold.

Who are some of NewLink Genetics Corp's key competitors?

Who owns NewLink Genetics Corp stock?

NewLink Genetics Corp's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.29%), FMR LLC (3.10%), Columbus Circle Investors (1.17%), Driehaus Capital Management LLC (0.73%), Teachers Advisors LLC (0.71%) and Bank of New York Mellon Corp (0.69%). Company insiders that own NewLink Genetics Corp stock include Brian Wiley, Carl W Langren, Charles J Jr Link, John B Henneman III and Joseph Saluri. View Institutional Ownership Trends for NewLink Genetics Corp.

Who sold NewLink Genetics Corp stock? Who is selling NewLink Genetics Corp stock?

NewLink Genetics Corp's stock was sold by a variety of institutional investors in the last quarter, including Bogle Investment Management L P DE, Renaissance Technologies LLC, TFS Capital LLC, Morgan Stanley, Piermont Capital Management Inc., Trexquant Investment LP, Alliancebernstein L.P. and Credit Suisse AG. View Insider Buying and Selling for NewLink Genetics Corp.

Who bought NewLink Genetics Corp stock? Who is buying NewLink Genetics Corp stock?

NewLink Genetics Corp's stock was purchased by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Columbus Circle Investors, EAM Investors LLC, Ameriprise Financial Inc., MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., Bank of New York Mellon Corp and Endurant Capital Management LP. View Insider Buying and Selling for NewLink Genetics Corp.

How do I buy NewLink Genetics Corp stock?

Shares of NewLink Genetics Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NewLink Genetics Corp stock cost?

One share of NewLink Genetics Corp stock can currently be purchased for approximately $14.34.

Analyst Ratings

Consensus Ratings for NewLink Genetics Corp (NASDAQ:NLNK) (?)
Ratings Breakdown: 2 Hold Ratings, 3 Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $26.50 (84.80% upside)

Analysts' Ratings History for NewLink Genetics Corp (NASDAQ:NLNK)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/19/2017ValuEngineUpgradeSell -> HoldHighView Rating Details
5/15/2017Jefferies Group LLCReiterated RatingHold$18.00MediumView Rating Details
5/4/2017Cantor FitzgeraldSet Price TargetBuy$32.00MediumView Rating Details
4/22/2017Stifel NicolausReiterated RatingBuy$26.00MediumView Rating Details
3/30/2017SunTrust Banks, Inc.UpgradeHold -> Buy$12.00 -> $30.00HighView Rating Details
5/16/2016Robert W. BairdReiterated RatingBuyN/AView Rating Details
5/10/2016MizuhoLower Price TargetBuy$52.00 -> $20.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for NewLink Genetics Corp (NASDAQ:NLNK)
Earnings by Quarter for NewLink Genetics Corp (NASDAQ:NLNK)
Earnings History by Quarter for NewLink Genetics Corp (NASDAQ:NLNK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.82)($0.72)$2.68 million$2.76 millionViewListenView Earnings Details
2/28/2017Q416($0.66)($0.46)$4.31 million$12.70 millionViewListenView Earnings Details
11/1/2016Q3($0.60)($0.54)$3.83 million$15.35 millionViewN/AView Earnings Details
7/29/2016Q216($0.77)($1.12)$4.81 million$2.01 millionViewListenView Earnings Details
4/29/2016Q116($1.70)($0.82)$2.08 million$4.34 millionViewListenView Earnings Details
2/29/2016Q415($0.92)($0.75)$4.89 million$6.06 millionViewListenView Earnings Details
11/3/2015Q315($0.66)($0.55)$9.01 million$14.21 millionViewN/AView Earnings Details
7/31/2015Q215($0.70)($0.49)$4.32 million$7.45 millionViewListenView Earnings Details
5/5/2015Q115($0.22)$0.35$12.78 million$39.20 millionViewN/AView Earnings Details
2/26/2015Q414($0.78)$4.05$2.98 million$159.25 millionViewN/AView Earnings Details
11/6/2014Q314($0.41)($0.20)$0.31 million$2.80 millionViewN/AView Earnings Details
8/5/2014Q214($0.42)($0.33)$0.30 million$0.21 millionViewN/AView Earnings Details
5/6/2014Q1 2014($0.37)($0.33)$0.31 million$0.33 millionViewN/AView Earnings Details
3/11/2014($0.37)($0.31)ViewN/AView Earnings Details
11/11/2013Q3($0.33)($0.32)ViewN/AView Earnings Details
8/7/2013Q213($0.32)($0.28)$0.59 million$0.23 millionViewN/AView Earnings Details
5/6/2013Q113($0.28)($0.33)$0.41 million$0.30 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NewLink Genetics Corp (NASDAQ:NLNK)
2017 EPS Consensus Estimate: ($2.84)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.71)($0.71)($0.71)
Q2 20171($0.71)($0.71)($0.71)
Q3 20171($0.71)($0.71)($0.71)
Q4 20171($0.71)($0.71)($0.71)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for NewLink Genetics Corp (NASDAQ:NLNK)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NewLink Genetics Corp (NASDAQ:NLNK)
Insider Ownership Percentage: 12.00%
Institutional Ownership Percentage: 46.83%
Insider Trades by Quarter for NewLink Genetics Corp (NASDAQ:NLNK)
Institutional Ownership by Quarter for NewLink Genetics Corp (NASDAQ:NLNK)
Insider Trades by Quarter for NewLink Genetics Corp (NASDAQ:NLNK)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/15/2016Charles J Jr. LinkCEOSell25,000$17.86$446,500.00View SEC Filing  
1/6/2016Charles J. Jr. LinkCEOSell25,000$32.53$813,250.00View SEC Filing  
1/5/2016Brian WileyVPSell1,295$34.99$45,312.05View SEC Filing  
1/5/2016Carl W. LangreninsiderSell1,095$34.97$38,292.15View SEC Filing  
1/5/2016Charles J. Jr. LinkCEOSell5,001$35.06$175,335.06View SEC Filing  
1/5/2016John B. Henneman IIICFOSell175$35.74$6,254.50View SEC Filing  
10/7/2015Charles J. Jr. LinkCEOSell10,000$35.16$351,600.00View SEC Filing  
10/5/2015Charles J. Jr. LinkCEOSell15,000$37.36$560,400.00View SEC Filing  
7/13/2015Joseph SaluriDirectorSell5,000$50.42$252,100.00View SEC Filing  
7/6/2015Charles J Jr. LinkCEOSell20,000$44.65$893,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NewLink Genetics Corp (NASDAQ:NLNK)
Latest Headlines for NewLink Genetics Corp (NASDAQ:NLNK)
Source:
DateHeadline
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Upgraded at ValuEngine
www.americanbankingnews.com - May 19 at 3:28 PM
streetinsider.com logoNewLink Genetics (NLNK) Says Data from Clinical Study of Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at EHA
www.streetinsider.com - May 19 at 11:37 AM
finance.yahoo.com logoBiotech Stocks: Is ASCO Much Ado About Nothing?
finance.yahoo.com - May 19 at 11:37 AM
finance.yahoo.com logoData from Clinical Study of NewLink Genetics’ IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
finance.yahoo.com - May 18 at 8:08 AM
feeds.benzinga.com logoData from Clinical Study of NewLink Genetics' IDO Pathway Inhibitor, Indoximod, to Be Presented at the 22nd European Hematology Association Congress
feeds.benzinga.com - May 18 at 7:33 AM
streetinsider.com logoNewLink Genetics (NLNK) Says Data from Studies of Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO
www.streetinsider.com - May 17 at 11:48 PM
finance.yahoo.com logoData from Clinical Studies of NewLink Genetics’ Two Distinct IDO Pathway Inhibitors to Be Presented at ASCO 2017
finance.yahoo.com - May 17 at 6:47 PM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK - Business Wire (press release)
www.businesswire.com - May 16 at 10:13 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of NewLink Genetics Corporation - NLNK
finance.yahoo.com - May 16 at 10:13 AM
americanbankingnews.com logoZacks Investment Research Upgrades NewLink Genetics Corp (NLNK) to Hold
www.americanbankingnews.com - May 14 at 9:32 PM
americanbankingnews.com logoShort Interest in NewLink Genetics Corp (NLNK) Rises By 31.5%
www.americanbankingnews.com - May 13 at 7:20 AM
247wallst.com logoHow Ebola Stocks Are Responding After the Outbreak in the Congo
247wallst.com - May 12 at 7:29 PM
americanbankingnews.com logoNewLink Genetics Corp Forecasted to Earn FY2017 Earnings of ($2.53) Per Share (NLNK)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to NewLink Genetics Corp. : May 11, 2017
finance.yahoo.com - May 11 at 7:21 PM
finance.yahoo.com logoNewLink Genetics Corp. :NLNK-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017
finance.yahoo.com - May 9 at 11:32 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 9 at 9:02 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Announces Earnings Results, Beats Expectations By $0.10 EPS
www.americanbankingnews.com - May 8 at 7:32 PM
finance.yahoo.com logoNewLink Genetics to Participate in Upcoming Investor Conferences
finance.yahoo.com - May 8 at 12:18 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Expected to Post Quarterly Sales of $2.65 Million
www.americanbankingnews.com - May 7 at 8:56 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Given a $32.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 7 at 7:34 AM
seekingalpha.com logoNewLink Genetics' (NLNK) CEO Charles Link on Q1 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - May 6 at 12:09 AM
feeds.benzinga.com logoMid-Afternoon Market Update: California Resources Surges On Earnings Beat; ArcBest Shares Slide
feeds.benzinga.com - May 5 at 3:16 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Receives "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - May 5 at 12:14 PM
fool.com logo3 Intriguing Cancer Drugs With Data Coming at ASCO Next Month
www.fool.com - May 5 at 8:46 AM
americanbankingnews.com logo-$0.81 Earnings Per Share Expected for NewLink Genetics Corp (NLNK) This Quarter
www.americanbankingnews.com - May 5 at 7:56 AM
finance.yahoo.com logoInvestor Network: Newlink Genetics Corporation to Host Earnings Call
finance.yahoo.com - May 4 at 11:20 AM
finance.yahoo.com logoNewLink Genetics Reports First Quarter 2017 Financial Results and Updates Clinical Trial Guidance
finance.yahoo.com - May 4 at 11:20 AM
finance.yahoo.com logoNewLink reports 1Q loss
finance.yahoo.com - May 4 at 11:20 AM
americanbankingnews.com logoSomewhat Positive Press Coverage Extremely Likely to Affect NewLink Genetics Corp (NLNK) Stock Price
www.americanbankingnews.com - April 27 at 2:00 PM
finance.yahoo.com logoVaunted Ebola Vaccine Faces Questions
finance.yahoo.com - April 25 at 10:24 AM
americanbankingnews.com logoFavorable Press Coverage Very Likely to Impact NewLink Genetics Corp (NLNK) Share Price
www.americanbankingnews.com - April 23 at 6:15 PM
americanbankingnews.com logoStifel Nicolaus Reiterates "Buy" Rating for NewLink Genetics Corp (NLNK)
www.americanbankingnews.com - April 22 at 8:33 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Given Overweight Rating at Cantor Fitzgerald
www.americanbankingnews.com - April 22 at 7:58 AM
seekingalpha.com logoNewLink Genetics Corp.: Best Is Yet To Come
seekingalpha.com - April 21 at 6:43 PM
finance.yahoo.com logoNewLink Genetics Corp. – Value Analysis (NASDAQ:NLNK) : April 21, 2017
finance.yahoo.com - April 21 at 6:43 PM
fool.com logoShould Gilead Sciences Acquire NewLink Genetics?
www.fool.com - April 21 at 12:28 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Short Interest Down 3.5% in March
www.americanbankingnews.com - April 21 at 10:59 AM
feeds.benzinga.com logoNewLink Genetics Announces Presentation of Two Abstracts at ASCO
feeds.benzinga.com - April 21 at 8:29 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Getting Somewhat Favorable Press Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 10:35 PM
finance.yahoo.com logoNewLink Genetics Corp. breached its 50 day moving average in a Bullish Manner : NLNK-US : April 20, 2017
finance.yahoo.com - April 20 at 9:25 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - April 14 at 10:10 AM
americanbankingnews.com logo Analysts Expect NewLink Genetics Corp (NLNK) Will Post Earnings of -$0.81 Per Share
www.americanbankingnews.com - April 14 at 8:56 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Getting Positive Press Coverage, Study Shows
www.americanbankingnews.com - April 13 at 2:14 PM
finance.yahoo.com logoNewLink Genetics to Host Its First Quarter 2017 Financial Results Conference Call on May 4, 2017
finance.yahoo.com - April 13 at 8:16 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - April 8 at 9:14 PM
finance.yahoo.com logoETFs with exposure to NewLink Genetics Corp. : April 7, 2017
finance.yahoo.com - April 7 at 7:15 PM
americanbankingnews.com logoFY2017 EPS Estimates for NewLink Genetics Corp Reduced by Jefferies Group (NLNK)
www.americanbankingnews.com - April 7 at 5:49 PM
finance.yahoo.com logoNewLink Genetics Corp. breached its 50 day moving average in a Bearish Manner : NLNK-US : April 7, 2017
finance.yahoo.com - April 7 at 11:29 AM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Earns "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - April 6 at 9:00 PM
americanbankingnews.com logoNewLink Genetics Corp (NLNK) Given "Buy" Rating at Stifel Nicolaus
www.americanbankingnews.com - April 6 at 9:46 AM

Social

Chart

NewLink Genetics Corp (NLNK) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff